Marc S. Hoffmann, MD
Assistant Professor, Hematologic Malignancies and Cellular Therapeutics
Medical Director of Lean and Quality Improvement, Marc S Hoffmann
Medical Director of Lymphoma and Myeloma, Hematologic Malignancies and Cellular Therapeuticsmhoffmann@kumc.edu
Marc Hoffmann graduated magna cum laude from Yale University with a degree in Molecular Biophysics and Biochemistry. He then served as a Peace Corps volunteer in Guinea, West Africa prior to attending medical school at the University of Pennsylvania where he also completed internship and residency. He completed hematology and medical oncology fellowship training at MD Anderson Cancer Center and served as a Chief Fellow in his final year. His clinical and research interests are in lymphoma and CLL. He is the Chair of the Lymphoma/Myeloma Disease Working Group and serves as principal investigator on multiple clinical trials. In addition to his clinical work, he is Medical Director for Lean and Quality Improvement in the Cancer Center.
Education and Training
- BS, Molecular Biophysics and Biochemistry, Yale University, New Haven, CT
- MD, Medicine, University of Pennsylvania, Philadelphia, PA
- Internship, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
- Residency, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
- Clinical Fellowship, Hematology and Oncology, MD Anderson Cancer Center, Houston, TX
Licensure, Accreditations & Certifications
- Board Certification in Hematology, ABIM
- Board Certification in Medical Oncology, ABIM
- Enterprise Medication Safety Sub-Committee, Enterprise Medication Safety Sub-Committee, Member, 2019 - Present
- Committee on Cancer, Committee on Cancer, Member, 2018 - Present
- Lymphoma/Myeloma Disease Working Group, Lymphoma/Myeloma Disease Working Group, Chair, 2018 - Present
- American Society of Hematology, American Society of Hematology, Member, 2012 - Present
Clinically, Dr Hoffmann has a subspecialty clinic at a tertiary academic medical center specializing in the management of lymphoma and CLL patients. In addition to inpatient responsibilities, he sees approximately 70 unique outpatients per week with these diseases and manage their work-up, therapy and post-treatment surveillance. He gives grand rounds, continuing nursing education, and continuing medical education lectures locally and nationally concerning management of CLL and lymphoma.
Dr Hoffmann serves as the local principal investigator on all of our indolent non-Hodgkin lymphoma and CLL clinical trials. He is chair of our disease working group for lymphoma and myeloma that presents and subsequently votes on all clinical trials that open at our site. He is on the SWOG lymphoma subcommittee and assists with design and implementation of cooperative group trials in this domain.
Additionally, he serves as a medical director for quality within the cancer center. In this role, he has led multiple improvement projects and helps to manage the Cancer Center service line value stream. Selected projects include improving efficiency with infusion suites, development and rollout of home infusion services for cancer patients, and designing an oral chemotherapy process to optimize patient safety. This work has been presented at national and regional meetings.